Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 2794-2797, June 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knecht, R.
Right arrow Articles by Strebhardt, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knecht, R.
Right arrow Articles by Strebhardt, K.
[Cancer Research 59, 2794-2797, June 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Prognostic Significance of Polo-like Kinase (PLK) Expression in Squamous Cell Carcinomas of the Head and Neck1

Rainald Knecht2, Robert Elez2, Martin Oechler, Christine Solbach, Christoph von Ilberg and Klaus Strebhardt3

Department of Obstetrics and Gynecology [R. E., C. S., K. S.] and Department of Otorhinolaryngology [R. K., M. O., C. v. I.], School of Medicine, J. W. Goethe-University, 60590 Frankfurt, Germany

Previously, we demonstrated that the mammalian polo-like kinase (PLK), which participates in the regulation of the cell cycle, is a novel marker of cellular proliferation. Because current prognostic tools for the evaluation of patients with head and neck squamous cell cancer (HNSCC) need to be improved, we analyzed 89 patients and found elevated PLK expression in most tumors. Nodal stage as a crucial prognostic factor in HNSCC also correlated to PLK transcript levels (P = 0.0043). A Kaplan-Meier analysis showed that HNSCC patients with moderate versus high PLK expression survived significantly longer (5-year survival rates, 43% versus 12%; P = 0.0047). Interestingly, a combination of nodal stage and PLK expression contributed to discriminate patients with a better prognosis in the pN0/1 and pN2/3 groups, which could improve the definition of a suitable therapy.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
J.-E. Park, L. Li, J. Park, R. Knecht, K. Strebhardt, S. H. Yuspa, and K. S. Lee
Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay
PNAS, February 10, 2009; 106(6): 1725 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Jimeno, J. Li, W. A. Messersmith, D. Laheru, M. A. Rudek, M. Maniar, M. Hidalgo, S. D. Baker, and R. C. Donehower
Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
J. Clin. Oncol., December 1, 2008; 26(34): 5504 - 5510.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Koida, T. Ozaki, H. Yamamoto, S. Ono, T. Koda, K. Ando, R. Okoshi, T. Kamijo, K. Omura, and A. Nakagawara
Inhibitory Role of Plk1 in the Regulation of p73-dependent Apoptosis through Physical Interaction and Phosphorylation
J. Biol. Chem., March 28, 2008; 283(13): 8555 - 8563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Newer Cytotoxic Agents: Attacking Cancer Broadly
Clin. Cancer Res., March 15, 2008; 14(6): 1610 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. K. Srivastava, P. Bansal, T. Oguri, J. S. Lazo, and S. V. Singh
Cell Division Cycle 25B Phosphatase Is Essential for Benzo(a)Pyrene-7,8-Diol-9,10-Epoxide Induced Neoplastic Transformation
Cancer Res., October 1, 2007; 67(19): 9150 - 9157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G.-H. Ha, K.-H. Baek, H.-S. Kim, S.-J. Jeong, C.-M. Kim, F. McKeon, and C.-W. Lee
p53 Activation in Response to Mitotic Spindle Damage Requires Signaling via BubR1-Mediated Phosphorylation
Cancer Res., August 1, 2007; 67(15): 7155 - 7164.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. L. Lehman, R. Tibshirani, J. Y. Hsu, Y. Natkunam, B. T. Harris, R. B. West, M. A. Masek, K. Montgomery, M. van de Rijn, and P. K. Jackson
Oncogenic Regulators and Substrates of the Anaphase Promoting Complex/Cyclosome Are Frequently Overexpressed in Malignant Tumors
Am. J. Pathol., May 1, 2007; 170(5): 1793 - 1805.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Liu, N. Jiang, J. Wu, W. Dai, and J. S. Rosenblum
Polo-like Kinases Inhibited by Wortmannin: LABELING SITE AND DOWNSTREAM EFFECTS
J. Biol. Chem., January 26, 2007; 282(4): 2505 - 2511.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. L. Garland, C. Taylor, D. L. Pilkington, J. L. Cohen, and D. D. Von Hoff
A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors
Clin. Cancer Res., September 1, 2006; 12(17): 5182 - 5189.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
X. Liu, M. Lei, and R. L. Erikson
Normal cells, but not cancer cells, survive severe plk1 depletion.
Mol. Cell. Biol., March 1, 2006; 26(6): 2093 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Gartel and S. K. Radhakrishnan
Lost in Transcription: p21 Repression, Mechanisms, and Consequences
Cancer Res., May 15, 2005; 65(10): 3980 - 3985.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, and Y. Luo
Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals
Cancer Res., April 1, 2005; 65(7): 2698 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen
Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1
J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Ando, T. Ozaki, H. Yamamoto, K. Furuya, M. Hosoda, S. Hayashi, M. Fukuzawa, and A. Nakagawara
Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation
J. Biol. Chem., June 11, 2004; 279(24): 25549 - 25561.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer
Mol. Cancer Ther., May 1, 2004; 3(5): 641 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Liu and R. L. Erikson
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
PNAS, May 13, 2003; 100(10): 5789 - 5794.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. A. Walter, R. E. Cutler Jr., R. Martinez, M. Gishizky, and R. J. Hill
Stk10, a New Member of the Polo-like Kinase Kinase Family Highly Expressed in Hematopoietic Tissue
J. Biol. Chem., May 9, 2003; 278(20): 18221 - 18228.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. McGregor, A. Muntoni, J. Fleming, J. Brown, D. H. Felix, D. G. MacDonald, E. K. Parkinson, and P. R. Harrison
Molecular Changes Associated with Oral Dysplasia Progression and Acquisition of Immortality: Potential for Its Reversal by 5-Azacytidine
Cancer Res., August 15, 2002; 62(16): 4757 - 4766.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Kelm, M. Wind, W. D. Lehmann, and E. A. Nigg
Cell Cycle-regulated Phosphorylation of the Xenopus Polo-like Kinase Plx1
J. Biol. Chem., July 5, 2002; 277(28): 25247 - 25256.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Xie, H. Wu, Q. Wang, J. P. Cogswell, I. Husain, C. Conn, P. Stambrook, M. Jhanwar-Uniyal, and W. Dai
Plk3 Functionally Links DNA Damage to Cell Cycle Arrest and Apoptosis at Least in Part via the p53 Pathway
J. Biol. Chem., November 9, 2001; 276(46): 43305 - 43312.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. C. Macmillan, J. W. Hudson, S. Bull, J. W. Dennis, and C. J. Swallow
Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer
Ann. Surg. Oncol., October 1, 2001; 8(9): 729 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
J. P. Cogswell, C. E. Brown, J. E. Bisi, and S. D. Neill
Dominant-Negative Polo-like Kinase 1 Induces Mitotic Catastrophe Independent of cdc25C Function
Cell Growth Differ., December 1, 2000; 11(12): 615 - 623.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C. W. Conn, R. F. Hennigan, W. Dai, Y. Sanchez, and P. J. Stambrook
Incomplete Cytokinesis and Induction of Apoptosis by Overexpression of the Mammalian Polo-Like Kinase, Plk3
Cancer Res., December 1, 2000; 60(24): 6826 - 6831.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.